- Adjuvant
- Treatment after the main local treatment, often surgery, to lower recurrence risk.
- Aspiration
- Food, liquid or saliva entering the airway. It can occur without coughing.
- Biopsy
- Taking tissue or cells for laboratory diagnosis.
- CPS
- Combined Positive Score: a PD-L1 score involving staining in tumour and selected immune cells relative to viable tumour cells.
- Depth of invasion
- How far an oral tumour grows below the original tissue surface; different from tumour thickness.
- Dysphagia
- Difficulty swallowing.
- EBV
- Epstein–Barr virus, linked to many nasopharyngeal carcinomas.
- Extranodal extension
- Cancer growing beyond the capsule of an involved lymph node.
- HPV
- Human papillomavirus; persistent high-risk infection can cause some oropharyngeal cancers.
- IMRT
- Intensity-modulated radiotherapy, which shapes radiation dose around the target.
- Margin
- The edge of surgically removed tissue examined for cancer.
- Metastasis
- Cancer spread away from its original location. Regional nodes and distant organs have different staging meanings.
- Mucositis
- Inflammation and ulceration of the lining of the mouth or throat.
- Neoadjuvant
- Treatment given before the main local treatment.
- p16
- A protein stain used as a marker in the appropriate HPV-related cancer testing context.
- PEG
- A feeding tube entering the stomach through the abdominal wall.
- Resectable
- Potentially removable by surgery; whether surgery is appropriate also depends on fitness and function.
- Stoma
- A surgically created opening. After total laryngectomy the neck stoma is the only breathing route.
- TPS
- Tumor Proportion Score: percentage of viable tumour cells with relevant PD-L1 staining; not interchangeable with CPS.
- Trismus
- Reduced ability to open the mouth.
- Xerostomia
- Dry mouth.
References and evidence review
Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.